IL-23 promotes tumour incidence and growth (original) (raw)

• Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001)
  Article CAS Google Scholar
• Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002)
  Article ADS CAS Google Scholar
• Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004)
  Article CAS Google Scholar
• Yee, C. & Greenberg, P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nature Rev. Cancer 2, 409–419 (2002)
  Article CAS Google Scholar
• Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004)
  Article ADS CAS Google Scholar
• Marincola, F. M., Wang, E., Herlyn, M., Seliger, B. & Ferrone, S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24, 335–342 (2003)
  Article CAS Google Scholar
• Ganss, R., Arnold, B. & Hammerling, G. J. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 34, 2635–2641 (2004)
  Article CAS Google Scholar
• Langrish, C. L. et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96–105 (2004)
  Article CAS Google Scholar
• Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715–725 (2000)
  Article CAS Google Scholar
• Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002)
  Article CAS Google Scholar
• Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005)
  Article CAS Google Scholar
• Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003)
  Article CAS Google Scholar
• Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003)
  Article ADS CAS Google Scholar
• Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005)
  Article CAS Google Scholar
• Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003)
  Article CAS Google Scholar
• Gupta, J. W., Kubin, M., Hartman, L., Cassatella, M. & Trinchieri, G. Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon. Cancer Res. 52, 2530–2537 (1992)
  CAS PubMed Google Scholar
• Girardi, M. et al. The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747–755 (2003)
  Article CAS Google Scholar
• Stark, M. A. et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285–294 (2005)
  Article CAS Google Scholar
• Mueller, M. M. et al. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am. J. Pathol. 155, 1557–1567 (1999)
  Article CAS Google Scholar
• Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000)
  Article CAS Google Scholar
• Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000)
  Article CAS Google Scholar
• Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3, 133–146 (2003)
  Article CAS Google Scholar
• Lo, C. H. et al. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600–607 (2003)
  Article CAS Google Scholar
• Tiano, H. F. et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62, 3395–3401 (2002)
  CAS PubMed Google Scholar
• Lieberman, L. A. et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173, 1887–1893 (2004)
  Article CAS Google Scholar
• Khader, S. A. et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J. Immunol. 175, 788–795 (2005)
  Article CAS Google Scholar
• Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125–130 (2004)
  Article CAS Google Scholar
• Nagase, H., Mao, J. H. & Balmain, A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc. Natl Acad. Sci. USA 96, 15032–15037 (1999)
  Article ADS CAS Google Scholar
• Fusenig, N. E., Am, S. M., Boukamp, P. & Worst, P. K. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271–279 (1978)
  CAS PubMed Google Scholar
• Wysocka, M. et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25, 672–676 (1995)
  Article CAS Google Scholar